PFE: Sigvie-002 Trial Fails
Pfizer's Phase 3 Sigvie-002 trial of Sigvotatug Vedotin in advanced NSCLC did not meet primary endpoint of OS versus Docetaxel
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.